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Abstract
Diabetic eye disease is a leading cause of acquired blindness in the United States. Most cases of blindness secondary to diabetes
mellitus are preventable. In addition to exercise, proper diet, and aggressive glycemic control, patients with diabetes mellitus should be
educated to adhere to established guidelines for an annual dilated retinal evaluation. The ideal model of care for patients with diabetic
eye disease is an interdisciplinary, team-oriented approach with the patient as the central member of the healthcare team. The primary
purpose of this paper is to present an interdisciplinary approach to management of the ocular complications of diabetes mellitus and to
educate clinicians about diabetic eye disease.
Introduction
Diabetes Mellitus (DM) is a group of metabolic diseases
characterized by hyperglycemia resulting from defects of insulin
secretion and/or increased cellular resistance to insulin.
Chronic hyperglycemia and other metabolic disturbances lead
to long-term tissue and organ damage involving the eyes,
kidneys, nervous, and vascular systems.1 Classified as a
“chronic disease epidemic” by the Centers for Disease Control
and Prevention, the prevalence of DM has increased
dramatically over the past forty years.2 This trend is especially
significant among minority populations and high-risk ethnic
groups (Native Americans, Hispanic Americans, African
Americans, and Asian Americans).3
Type 1 DM accounts for approximately 10% of all patients with
DM in the United States. Although it can occur at any age, Type
1 DM is more common in those under 30 and replaces the term
"insulin dependent diabetes mellitus." Type 1 DM is a disease
of fat, carbohydrate, and protein catabolism caused by a lack of
circulating insulin. Patients require exogenous insulin to reverse
this metabolic abnormality, prevent ketosis, and decrease
hyperglucagonemia. Type 1 DM is thought to be an
autoimmune disease with specific organ involvement; it results
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from destruction of insulin-producing beta cells in the
pancreas.4,5 Examination of islet tissue obtained from
pancreatic biopsy from patients with recent onset Type 1 DM
confirmed the presence of this “insulitis.”6
Current thinking on the pathogenesis of Type 1 DM involves an
interaction of genetic and infectious or environmental factors
that trigger an immune mediated reaction. The appearance of
autoantibodies constitutes a response against altered beta cell
antigens or molecules in beta cells that resemble viral proteins.7
Environmental agents that have been theorized to trigger this
sequence include viruses, toxic chemicals, early exposure to
cow's milk, and cytotoxins.7,8 Recent evidence also suggests a
role for vitamin D in the pathogenesis and prevention of Type 1
DM.8
Type 2 DM is the most common form of DM worldwide; its
incidence increases with age, especially after age 40. The
condition can vary from predominant insulin resistance with
relative insulin deficiency to a predominant insulin-excretory
defect with insulin resistance.9 Caloric excess (usually
consisting of a high-fat diet) accompanied by inadequate caloric
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expenditure (lack of physical activity) in a susceptible genotype
is presumed to be the cause of Type 2 DM.10 Type 2 DM in
children is on the rise, especially in the high-risk ethnic groups.
Most of these children are between 10 and 19 years old, have
infrequent or mild diabetic ketoacidosis, are obese, and have a
strong family history of DM.11
DM cannot be optimally managed in isolation. The benefits of
an integrated, interdisciplinary team model for management of
chronic illness are well documented. For example, chronic
disease management systems (CDMS) have been
implemented for patients living with (or at risk for developing)
conditions such as asthma, congestive heart failure, and
hypertension. Application of this model, however, is still
relatively new to DM. Successful adoption of this team concept
requires a paradigm shift in how providers, including allied
health care professionals, and patients view their respective
roles in the process. Recognition of the complexity of DM
treatment has prompted both the American Association of
Diabetes Educators (AADE) and the American Diabetes
Association (ADA) to endorse team management as the
optimal model for care.12
The ADA recommends that all adults aged 45 years and older
be screened for DM.1 Patients who at higher risk should be
screened at younger ages and more frequently. In general,
high-risk individuals are:
·
·
·
·
·
·
·

Obese: > 120% desirable body weight or body mass index
>27 kg/m2
A first degree relative of someone with DM
Members of high-risk ethnic groups (African-American,
Hispanic, Native American)
Women diagnosed with gestational diabetes or with babies
weighing more than 9 pounds
Hypertensive (blood pressure >140/90)
Those with HDL cholesterol less than 35 mg/dl and/or
triglyceride level greater than 250 mg/dl
Those who have had impaired fasting glucose or impaired
glucose tolerance on previous testing4

People with diabetic retinopathy (DR) represent a large
segment of the population with vision impairment.13 In the
1990s, blindness secondary to DR in the United States was
estimated to cost 500 million dollars annually.14 According to
the Centers for Disease Control, DM was the sixth leading
cause of blindness in the United States in 2000.2 By 2004, it
was the leading cause of blindness for persons younger than
75.11 Both the prevalence and the economic burden of the
disease are on the rise.
Severe vision loss from DR is often preventable with timely
detection and treatment. One study has shown that in 90% of
the cases, blindness secondary to DR is preventable.15
Unfortunately, studies of managed care organizations have
shown that fundus examination for diabetic retinopathy has
been the quality of care indicator with the lowest compliance
© The Internet Journal of Allied Health Sciences and Practice, 2007
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measure.16
The primary purpose of this paper is to present an
interdisciplinary approach to management of the ocular
complications of DM and to educate clinicians about diabetic
eye disease. In addition, we review those risk factors that are
most predicative of DR and outline the clinical features,
diagnosis, and treatment of those sight-threatening elements of
DR. By identifying risk factors and early signs of DR, clinicians
can provide early monitoring and/or treatment to those patients
in need, within the team-oriented model of care.
A Global Approach to DM Management
Optimal DM care cannot be achieved in isolation. One
professional or profession cannot provide comprehensive
service to diabetic patients that will appropriately meet their
diverse needs. For example, optometric physicians, though
skilled primary eye care providers, cannot adequately care for
patients with diabetic podiatric problems.
An interdisciplinary team approach to DM management is
essential. A recent American Public Health Association
statement recommended comprehensive (interdisciplinary) care
for all persons with DM, including high-risk populations of
African-Americans, Hispanic Americans, and Native Americans.
The Diabetes Control and Complications Trial (DCCT) provided
evidence that a model of interdisciplinary team care resulted in
improved metabolic control and better overall outcomes.17 A
team-oriented model is maximally effective when it becomes an
interdisciplinary commitment on the part of several individuals.
We advocate an interdisciplinary concept of care using a
patient empowerment-based model.
An effective DM management team should have a coordinator.
It is common for the primary care physician (PCP) to oversee
the entire team. Without a coordinator, the care can be
fragmented and cost-ineffective. The Indiana Chronic Disease
Management Program (ICDMP) implements Nurse Care
Managers who work with the patient’s PCP to deliver a
consistent message to patients regarding management of their
chronic disease. Nurse Care Managers also provide one-onone assessments and education to patients during an
intervention period and subsequent reinforcement phase. The
coordinator may also be a Certified Diabetes Educator, or
health care professional with expertise in DM education that
has met eligibility requirements and successfully completed a
certification examination.
Chronic disease management has long been accomplished
through the use of a compliance-based model. Whether the
treatment is medical, surgical, or rehabilitative, patients were
simply told what to do, and were expected to comply with the
management plan. Using this model, the decision-making
power was thought to rest solely with the health professionals.
The compliance model, however, does not take into account
one crucial factor: people make their own choices.18 These
choices are based upon an individual’s values, goals, needs,
fears, and problems as human beings living with DM and other
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diseases.
Anderson and colleagues describe a DM management
program, based on patient empowerment, which was tested on
patients at the University of Michigan. In a randomized
controlled trial, measurable improvements in attitude and selfefficacy, as well as a significant (0.71%) reduction in
glycosylated hemoglobin resulted from this chronic disease
management program.19
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the health professionals and the patient, who is no longer a
passive member of the team, but a primary decision-maker.20
Patient empowerment requires effective patient education. This
can be accomplished via several avenues. Each member of the
healthcare team can provide in-office education and
supplement this with appropriate written materials. The case
manager or chronic care coordinator can facilitate the overall
patient education component. Various DM wellness programs
are available through hospitals and outpatient clinics.

Table 1 lists several potential members of the interdisciplinary
In the empowerment-based model, people accept the fact that
DM management team, with the patient as the central member.
DM is part of their life, and they adapt to live well despite this
Other professionals and sub-specialists may be added to the
challenge. This model gives people the opportunity to explore
team on a case-by-case basis.
healthy coping strategies, drawing upon the expertise of each
member of the health care team. The power is split between
______________________________________________________________________________________________
Table 1:Composition of an Interdisciplinary Diabetes Mellitus Management Team
Optometric physicians
Ophthalmologists/Retinologists
Primary care medical physicians
Other sub-specialists (i.e. Endocrinologists, Geriatric Medicine, Neurologists,
Rehabilitative medicine)
Physician assistants, Nursing professionals
Occupational therapists
Physical therapists
Pharmacists, Certified diabetes educators (CDE)
Dentists
Dietitians, Nutritionists
Podiatrists
Behavioral scientists
______________________________________________________________________________________________
Economic Impact of Early Detection and Treatment of DR
There is overwhelming evidence of the efficacy of treatment of
DR. In Iceland, all persons with type 1 DM have been screened
for DR through a central system since 1980. Using this system,
only one case of blindness secondary to DR has been reported
since the 1990s.21 The results of this screening program and
others like it supports the view that identification (of DR) and
timely intervention can be successful on a large-scale basis, at
least in type 1 DM. The cost of undiagnosed DM is higher than
the expense associated with managing the pathological
endpoints. These already account for 1 of every 7 health care
dollars spent in the United States, a number that is expected to
rise dramatically in the coming years.22,23 Blindness alone has
been associated with increased length of hospital stay, nursing
© The Internet Journal of Allied Health Sciences and Practice, 2007

home placement, and hip fracture.24-27 These facts indicate a
need for timely detection and management of DR.
But do these team-oriented, chronic disease management
systems save money and improve patient outcomes? In a
report of simultaneous short-term savings and quality
improvement associated with a health maintenance
organization (HMO)-sponsored disease management program,
the authors evaluated an interdisciplinary program for patients
with DM. This study compared health care costs for patients
who fulfilled Health Employer Data and Information Set
(HEDIS) criteria for DM and were in an HMO-sponsored
disease management program with costs for those not in the
disease management program. In this HMO, an opt-in DM
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disease management program appeared to be associated with
a significant reduction in health care costs and other measures
of health care use. There was also a simultaneous
improvement in HEDIS measures of quality care and patient
outcomes. The percentage of patients that underwent HbA1c
testing as well as lipid, eye, and kidney screening were 96.6,
91.1, 79.1, and 68.5%, respectively among program patients,
compared with 83.8, 77.6, 64.9, and 39.3%, respectively
among non-program patients. These data suggest that patient
education, clinical guidelines with provider teaming, and
financial performance need not be mutually exclusive.28
We as members of the provider team must address the various
barriers to care that patients living with DM face. In a recent
study, people with DM were more likely to have had an eye test
within the last 2 years if they had seen a healthcare provider or
had one of various health checks, including checks not related
to DM, within the same time frame. These results suggest that
people who take an interest in their general health may also be
more aware of the importance of eye examinations to avoid
vision loss. Eye health promotion activities, therefore, need to
broaden their reach to approach from outside the health sector,
targeting people with DM who normally do not receive health
checks. The importance of dilated eye examinations for people
with DM needs to be further promoted by all providers.29
There must exist an environment of collegiality among team
members that is mutually respectful, trustful, and non-
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competitive. Information needs to flow between members of the
health care team. The primary care provider (PCP) needs to
know what is happening with his/her patient's eyes, and too
often eye care providers fail to complete the communication link
back to the PCP. Likewise, specific information from the PCP or
team coordinator about the patient's DM history and current
level of glycemic control is invaluable to the eye care provider.
We recommend that each member of the team concentrate on
their own area of expertise, but communicate their results and
recommendations to the others clearly, and at times, with
sufficient tact. We must keep our eyes on the ultimate goal: a
well adjusted, empowered, optimally functioning person who
has overcome the challenges that DM poses.
Complications of Diabetes Mellitus
DM has several systemic complications. These include heart
disease, kidney failure and circulatory problems, potentially
leading to amputation and blindness. Additionally, neuropathies
can produce functional difficulties for the patient. Common
systemic symptoms may include polyuria, polydipsia,
polyphagia, unexplained weight changes, dry mouth, pruritus
leg cramps or pains, impotence, delayed healing of bruises or
wounds, and recurrent infections of the skin, genitalia or urinary
tract. Systemic complaints are more common in patients with
type 1 DM. Patients with type 2 DM are frequently
asymptomatic. Table 2 outlines DM-related systemic
complications.9

________________________________________________________________________________________________________________________________________________________________________

Table 2: Systemic Complications of DM
Cardiovascular Disease
Atherosclerosis
Stroke
Myocardial Infarction
Hypertension

Kidney Disease
Kidney failure requiring
transplantation or dialysis

Nerve Disease
Circulatory
Amputations
Gum Disease
Pain
Reduced Wound Healing
Loss of Sensation
Muscle Weakness
_____________________________________________________________________________________________________________
Common ocular symptoms of undiagnosed DM include a recent
onset of blurred or fluctuating vision, diplopia (double vision),
and ocular dryness. A loss of fine detail in central vision is
typically one of the first and most common symptoms of DR.
Night vision problems, flashes, and floaters are other, less
common symptoms of DR. The disease can eventually lead to
retinal detachment, glaucoma, and blindness at its most
severe.
The symptom of fluctuating vision may be caused by refractive
error shifts. With elevated levels of glucose, the glycolytic
© The Internet Journal of Allied Health Sciences and Practice, 2007

pathway backs up, forcing some of the glucose to shift into the
polyol metabolic pathway. In this pathway, aldose reductase
converts glucose to sorbitol. Sorbitol can act osmotically to shift
fluid into cells. As glucose levels drop, sorbitol levels also fall
and fluid shifts out of cells. These osmotic shifts change the
shape of the eye's crystalline lens, thus altering a patient's
refractive error, resulting in blur and visual fluctuation.30
Eventually, most people with DM will develop some degree of
DR.31 DR is common in both Type 1 and Type 2 DM, thereby
affecting a broader range of people than many other conditions.
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and dysfunction of endothelial cells. Out-pouchings of the
DR also has a wide spectrum of severity and may not progress
capillaries, called microaneurysms, are frequently the earliest
uniformly, implying that people with DR may have varying
clinically detectable sign of DR. DR results from an alteration in
degrees of residual vision, regardless of age and other factors.
retinal blood flow that degrades performance of the retina.32,33
The exact cause of microvascular complications is not known.
Over time, non-perfusion of retinal capillaries weakens the
The Diabetes Control and Complications Trial (DCCT) showed
capillary walls, resulting in bulging, leaking, or scarring of blood
that control of hyperglycemia decreased microvascular
vessels. With tissue ischemia, angiogenic factors are released,
complications. DR is a small vessel disease that affects the
causing new blood vessel formation (neovascularization) as
capillaries before the larger vessels are affected. Pericytes
well as leakage from normal vessels.34 Table 3 outlines the
provide structural support for the endothelial cells. An early
many ocular manifestations of DM.35
finding in DM is the loss of pericytes, which may cause leakage
______________________________________________________________________________________________
Table 3: Ocular Complications of DM
Functional vision problems
·
·
·
·
·
Cornea
·
·
·

Color vision deficiencies
Refractive error changes
Accommodative dysfunction
Visual field defects
Reduced contrast sensitivity
Reduced sensitivity
Reduced wound-healing
ability
Increased frequency of
abrasions or recurrent
erosion syndrome. (See
Figure 1)

Vitreous
· Hemorrhage in proliferative
retinopathy

Extraocular muscle anomalies
· Mononeuropathies involving
third, fourth, or sixth cranial
nerves

External ocular anomalies
· Sluggish pupillary reflexes
· Bulbar conjunctival
microaneurysms
· Tear film deficiencies, resulting
in dry eye syndrome

Iris

Lens
·

·
·
·

Retina
·
·
·
·

Depigmentation
Rubeosis iridis
Neovascular glaucoma

Nonproliferative retinopathy
(NPDR)
Proliferative retinopathy
(PDR) (See Figures 3 and 4)
Macular edema (CSME) (See
Figure 5)
Tractional retinal detachment

Higher prevalence of cataracts
(See Figure 2)

Optic Nerve
· Papillopathy
· Ischemic optic neuropathy
· Higher incidence of open angle
glaucoma
· Neovascular glaucoma

_____________________________________________________________________________________________
Risk Factors for Diabetic Retinopathy
DR affects 40-45% of the approximately 18 million Americans
who have DM.31 Risk factors for the development or
progression of DR include increasing duration of disease (DM),
hypertension, hyperglycemia, puberty, pregnancy, renal failure,
hyperlipidemia, HIV infection, smoking (disputed), and
genetics.36 However, evaluations of HEDIS data show that only
35% to 50% of known diabetics undergo an annual retinal
evaluation.37

Table 4 summarizes the results of the Wisconsin Epidemiologic
Study of Diabetic Retinopathy (WESDR).38,39 WESDR
demonstrated how the increasing duration of DM in both Type 1
and Type 2 patients increases the incidence of ocular
manifestations.40,41 In WESDR, higher frequencies of
proliferative diabetic retinopathy (PDR) were present in
younger-onset men as compared with younger-onset women,
but there was no significant difference in the 10-year incidence
or progression of DR.42

______________________________________________________________________________________________
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Table 4: WESDR Study: Duration of Diabetes Mellitus
Type of DM
Type 1

Duration of DM
5 years
>10 years

Ocular Manifestations
Possible ocular manifestations
60% have some retinopathy
Virtually all patients have some
degree of retinopathy. 25%
progress to proliferative diabetic

>15 years

retinopathy.
50% progress to proliferative

Type 2

>20years

retinopathy.

At diagnosis

20% have retinopathy
4% progress to proliferative

>4 years

retinopathy.
60-80% have some retinopathy. Up
to 20% progress to proliferative

>15 years

retinopathy.

______________________________________________________________________________________________
Figure 1: Corneal abrasion in a patient with DM

______________________________________________________________________________________________
Figure 2: Dense cataract in a patient with DM
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______________________________________________________________________________
Figure 3: Proliferative retinopathy with large pre-retinal hemorrhage (Photo courtesy of Alan Kabat, OD)

______________________________________________________________________________
Figure 4: Proliferative retinopathy with vitreous involvement

_____________________________________________________________________________________________________________
Figure 5: Macular edema with a "circinate ring" of hard exudates in a patient with DM

_____________________________________________________________________________________________________________
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(ETDRS) grading system was used to classify each fundus.44-45
We recently reported the results of a study of risk factors for
43
We found that duration of DM significantly predicted the
DR. The factors that we studied were age, race, gender,
presence of retinopathy (P<.001). Specifically, as duration of
smoking history, age at initial diagnosis of DM, duration of DM,
DM increased, the odds of developing DR increased by 30%.
and whether insulin was used for glycemic control. Subjects
Figure 6 shows the increasing prevalence of DR with increasing
with DM, aged 29-79 years, underwent a health history survey
duration of DM for patients in our study. Our results are
and ophthalmic examination, including a dilated fundus
consistent with those of WESDR.36,38-43,46
evaluation. The Early Treatment of Diabetic Retinopathy Study
_____________________________________________________________________________________________________________
Figure 6: Prevalence of Diabetic Retinopathy as a Function of Duration of DM

_____________________________________________________________________________________________________________
Clinical Features and Classification of Diabetic
Retinopathy
The clinical features of non-proliferative diabetic retinopathy
(NPDR) include dot, blot, and flame-shaped hemorrhages,
microaneurysms, intraretinal microvascular abnormalities
(IRMA), venous beading, hard exudates, “cotton wool-like”
infarct, and macular edema. For an eye to be classified as
proliferative diabetic retinopathy (PDR), it must have one or
more of the following: neovascularization of the optic disc
(NVD), neovascularization elsewhere (NVE), and a vitreous or
preretinal hemorrhage associated with NVE.47
As mentioned previously, microaneurysms are out-pouchings of
retinal capillaries. IRMA are dilated and tortuous capillaries and
are good indicators of progressive DR. Venous beading is a
focal irregularity in the caliber of retinal veins and is a strong
predictor for the development of neovascularization. Cottonwool spots represent focal infarcts of the retinal nerve fiber
layer. Ruptured microaneurysms, leaking capillaries, and IRMA
may result in intraretinal hemorrhages. The ophthalmoscopic
appearance of these hemorrhages is consistent with the retinal
level in which they occur. Hemorrhages in the retinal nerve fiber
layer have a flame-shaped appearance and coincide with the
structure of the nerve fiber layer. Hemorrhages deeper in the
retina, assume a pinpoint, blot, or dot shape and are more
characteristic of DR.
Leakage from peri-foveal vessels causes macular edema,
which, if left untreated, may result in permanent vision loss.
© The Internet Journal of Allied Health Sciences and Practice, 2007

This edema can occur at any stage of retinopathy. The
classification of clinically significant macular edema (CSME)
from the ETDRS grading system requires the presence of one
or more of the following: thickening of the retina within 500
microns (1/3 optic disc diameter) from the center of the center
of the macula, hard exudates within 500 microns from the
center of the macula with associated thickening of the adjacent
retina, and a zone or zones of retinal thickening greater than 1
optic disc diameter (DD) in size, any portion of which is within 1
DD from the center of the macula.44,45
Diagnosis and Treatment of Diabetic Retinopathy
Treatment for NPDR (Without CSME)
NPDR is significant because of its rate of progression into PDR.
Thus, the stage of NPDR at the initial diagnosis dictates the
follow-up schedule for the patient. Mild NPDR has a 5% risk of
progressing to PDR in 1 year and a 15% risk of progression to
high-risk PDR within 5 years. Moderate NPDR has a 12-27%
risk of progressing to PDR in 1 year and a 33 % risk of
progressing to high-risk PDR within 5 years. Severe NPDR has
a 52% risk of progressing to PDR in 1 year and a 60% risk of
progressing to high-risk PDR within 5 years.9,44
Management of NPDR centers on stabilizing and arresting the
progression of DR. The DCCT showed that intensive DM
control, involving multiple daily blood sugar measurements,
nutritional counseling, medical evaluations every 3 months, and
glycosylated hemoglobin evaluation every 3 months, decreased
the development and progression of retinopathy. Using an
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interdisciplinary approach, the ADA recommends close blood
pressure and cholesterol monitoring, as well as smoking
avoidance, exercise, and weight control. DM patients without
retinopathy or with mild NPDR should be monitored with dilated
fundoscopy on an annual basis. Those with moderate-to-severe
NPDR should be monitored with more frequent dilated
fundoscopy. Instruction on DM self-management by a Certified
Diabetes Educator is a mainstay of interdisciplinary
management.
Treatment for PDR (Without CSME)
In cases of PDR and CSME, fluorescein angiography is needed
to detect treatment landmarks and patterns of leakage.
Injecting a fluorescein dye into the arm and subsequently
photographing the retina through a dilated pupil using a special
filter accomplishes this test.
Treatment of PDR usually involves laser surgery to seal leaking
vessels and prevent the development of aberrant, new blood
vessels. These new, weaker blood vessels can rupture, scar,
and cause death of retinal tissue. Early treatment of PDR with
photocoagulation surgery reduces the risk of severe vision loss
by at least 50-60 percent. The various structures of the eye
respond to different wavelengths of laser light. This
necessitates different types of laser treatment, depending on
the location of the disease process within the eye. In some
cases of PDR, a vitrectomy procedure (removal of the vitreous
body) is performed. Indications for vitrectomy surgery include
vitreous hemorrhage that blocks the view of the retina, dense
premacular hemorrhage, complicated retinal detachment, and
severe neovascular proliferation that is non-responsive to laser
treatment.48,49
Treatment of CSME
Optical coherence tomography (OCT) is an in-vivo imaging
technology that displays different layers of retinal structure
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clearly and processes the images objectively. OCT can be
helpful in establishing the diagnosis of CSME in a non-invasive
manner. In OCT, CSME is represented by an increase in retinal
thickening due to intraretinal fluid leakage.
The goal of laser treatment for CSME is not to improve vision,
but to try to slow visual loss as a result of chronic edema and
resultant tissue damage. Focal or grid laser photocoagulation
exerts its beneficial effect on macular edema by producing
coagulation necrosis. Patients with macular edema that is not
clinically significant should be followed every 3 to 6 months.
Conclusions
The longer a patient has been living with DM, the more likely it
is that he/she will develop DR.43,50 DR is treatable. In addition to
exercise, proper diet, and aggressive glycemic control, patients
with DM should be educated to adhere to guidelines
established by the American Optometric Association for an
annual dilated fundus evaluation. By detecting diabetic
retinopathy earlier, many of its potentially sight- threatening
complications could be reduced or prevented.
In interdisciplinary care, providers share a common
professional identity and purpose. Egos are put aside and roles
of the team members remain flexible. Interdisciplinary DM
management can result in fewer long-term diabetic
complications. Allied health care providers have a significant
role in caring for patients with DM. Owing to their diverse and
expanding roles in health care delivery systems, allied health
professionals are in a unique position to work with eye care
practitioners and other team members to improve the quality of
life and health of their patients living with diabetes. By properly
screening for symptoms such as visual blur and for ocular
complications such as retinopathy, allied health professionals
can facilitate appropriate diagnostic testing and treatment to
reduce the likelihood of significant vision loss.
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